According to some surveys, over 90% of all physicians have some interactions with pharmaceutical and device companies, and over 80% received something of value from such companies, including food, honoraria, consultant fees and research grants. In the past years, several states have enacted laws requiring pharmaceutical companies to report some of these interactions. In addition, recent corporate integrity agreements have contained requirements for companies to disclose their financial relationships with healthcare professionals.

 

With the passage of the federal Physician Payment Sunshine Act, the need to accurately document and aggregate your company's spend on physicians has increased dramatically. All pharmaceutical, device and biotech companies will be required to report detailed financial relationships with prescribers throughout the United States. While the first report is not due until March 2013, companies need to start gathering extensive information starting January 1, 2012. Failure to include information can lead to significant penalties. Furthermore, inaccurate reports can have an impact on your company's relationships with healthcare providers.

 

Companies that have already begun collecting and reporting healthcare provider payments under state law and/or corporate integrity agreements may have to alter some of their disclosures to provide more transparency. Companies that have not begun to publicly disclose physician payments have a lot of catching up to do. While there is still some time to start capturing the data, prudent companies should consider starting this process as soon as possible, as this task can be daunting, and technical solutions may need to be devised, implemented and tested well in advance of the January 1, 2012 date for collecting this data.

 

Key Details Provided:

Who Should Purchase:

You will benefit from purchasing this webseminar if you are a senior-level professional at a pharmaceutical, biotech or medical device company with responsibilities or involvement in the following areas:

About Our Presenter:

Mark D. Lurie, Principal, Lurie Law Firm, LLC

 

Mark Lurie is the principal of the Lurie Law Firm, which focuses on compliance advice and services for the pharmaceutical and medical device industries. The firm also focuses on employment law and litigation, with a particular emphasis on whistleblower allegations and internal investigations.

 

Before forming his own legal practice, Mark was the Vice President and Chief Ethics and Compliance Officer at Eisai Corporation of North America, a mid size pharmaceutical company. Mark was responsible for the creation, oversight and evolution of the company's compliance function for more than six years, and chaired Eisai's US compliance committees. In that role, Mark created risk assessment rolls and prioritized risks, and created policies and procedures (including codes of conduct, policies on interactions with healthcare providers, Foreign Corrupt Practices Acts policies and procedures, Fair Market Value policies and procedures, a groundbreaking system to track payments to healthcare providers, and other policies and procedures). Mark provided substantial and ongoing training to all employees, both live and electronically. Mark also participated in due diligence activities, conducted and oversaw investigations, and prioritized audits and monitoring activities. Prior to heading its compliance efforts, Mark was Eisai's senior employment counsel, responsible for day-to-day employment advice, oversight and resolution of employment disputes, conducting internal investigations, providing training, and creation of employment-related policies, as well as oversight of all litigations.

 

Mark was a partner in the Labor and Employment Group of Epstein Becker & Green before joining Eisai. Mark successfully litigated numerous whistleblower, discrimination, harassment, retaliation, breach of contract and other employment-related disputes. Mark was also an employment litigator at Proskauer Rose and McCarter & English. Mark has practiced in state and federal courts, at both the trial and appellate levels, as well as in administrative and arbitration proceedings.